Exagen (XGN) Competitors

Personalis (NASDAQ:PSNL) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.

Is PSNL or XGN more profitable?

Exagen has a net margin of -30.36% compared to Personalis' net margin of -104.52%. Personalis' return on equity of -66.07% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-104.52%	-66.07%	-41.34%
Exagen	-30.36%	-92.58%	-33.74%

Do insiders and institutionals believe in PSNL or XGN?

61.9% of Personalis shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 3.8% of Personalis shares are held by company insiders. Comparatively, 26.1% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the MarketBeat Community prefer PSNL or XGN?

Personalis received 101 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 68.31% of users gave Personalis an outperform vote while only 58.54% of users gave Exagen an outperform vote.

Company	Underperform	Outperform
Personalis	Outperform Votes 125 68.31%	Underperform Votes 58 31.69%
Exagen	Outperform Votes 24 58.54%	Underperform Votes 17 41.46%

Do analysts recommend PSNL or XGN?

Personalis presently has a consensus price target of $7.80, suggesting a potential upside of 108.84%. Exagen has a consensus price target of $7.50, suggesting a potential upside of 23.86%. Given Personalis' higher possible upside, analysts plainly believe Personalis is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Exagen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, PSNL or XGN?

Personalis has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Which has preferable valuation and earnings, PSNL or XGN?

Exagen has lower revenue, but higher earnings than Personalis. Exagen is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$84.61M	3.90	-$108.30M	-$1.37	-2.73
Exagen	$55.64M	1.95	-$23.69M	-$0.83	-7.30

Does the media prefer PSNL or XGN?

In the previous week, Personalis had 1 more articles in the media than Exagen. MarketBeat recorded 4 mentions for Personalis and 3 mentions for Exagen. Personalis' average media sentiment score of 0.92 beat Exagen's score of 0.86 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Personalis beats Exagen on 11 of the 17 factors compared between the two stocks.